The cannabis sector remains in a correction, with both marijuana and CBD stocks trending lower, giving up some of their early-year gains—and perhaps building a bottom here.
In the meantime, more and more peripheral companies are getting in on the action, and we have been increasing our exposure to these in recent weeks while still holding substantial cash.
This week we’re selling one more of the pure-play marijuana companies, raising the portfolio’s cash level to about 27%.
Full details in the issue.